biologic

Tremfya

guselkumab

Loss of exclusivity—loss of exclusivity
CompanyJanssen Biotech →See this company's full patent-cliff portfolio

Drug detail

Brand nameTremfya
Active ingredientguselkumab
Strength200MG/2ML (100MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.